Highly Potent BTK Degradation Induced By NRX0492 As a Therapeutic Strategy for CLL

伊布替尼 布鲁顿酪氨酸激酶 慢性淋巴细胞白血病 断点群集区域 癌症研究 B细胞受体 B细胞 生物 白血病 免疫学 酪氨酸激酶 抗体 信号转导 细胞生物学 受体 生物化学
作者
Deyi Zhang,Hailey M. Harris,Aileen Kelly,DANIEL W. ROBBINS,May Tan,Timothy G. Ingallinera,Neil Bence,Arthur Sands,Sivasubramanian Baskar,Sarah E. M. Herman,Adrian U. Wiestner
出处
期刊:Blood [Elsevier BV]
卷期号:134 (Supplement_1): 174-174 被引量:3
标识
DOI:10.1182/blood-2019-126921
摘要

B-cell receptor (BCR) signaling plays an essential role in normal B-cell development and is a key driver of proliferation and survival of chronic lymphocytic leukemia (CLL) B cells. BCR signals through BTK to NF-ĸB. Targeted inhibition of BTK with ibrutinib, a first-in-class covalent BTK inhibitor, is highly effective in treating CLL and related B-cell malignancies. However, progressive disease on continuous therapy with ibrutinib has been associated with mutations in BTK and PLCG2. Most patients with acquired resistance and progressive CLL on ibrutinib have mutations in BTK affecting the cysteine at position 481 (C481) to which ibrutinib covalently binds. The common C481S mutation increases IC50 with ibrutinib from low nM to μM concentrations. The emergence of specific BTK mutations in ibrutinib resistant CLL further validate BTK as a valuable therapeutic target in CLL. Therefore, agents that can target C481 mutant BTK are of great interest, and non-covalent BTK inhibitors have entered clinical trials. Here we investigated an alternative approach using a chimeric targeting molecule: NRX0492. NRX0492 combines two molecules: a "hook" that binds BTK with a "harness" that recruits ubiquitin ligases that mediate proteasome-dependent degradation of BTK. In cell line models, NRX0492 induce both wild-type and C481S mutant BTK degradation efficiently and specifically. Here we sought to define the on-target effects of NRX0492 in primary CLL cells in vitro and in vivo and to test NRX0492 against ibrutinib-resistant primary CLL cells. CLL cells were treated at densities of 5 × 106 cells/ml in 24-well plates with NRX0492, ibrutinib, the "hook" moiety devoid of the ubiquitin ligase binding moiety, or DMSO. BTK levels were quantified by Western blotting and flow cytometry. The mean ED50 and ED90 of NRX0492 for BTK degradation at 4 hours was 0.18nM and 0.5nM, respectively. At ED90 concentrations, mean cell viability of cultures treated with NRX0492 was 97.5%, and not different from viability of controls. Incubation at ED50 up to 24 hours also did not induce cell death. A lack of substantial cytotoxic activity with BTK degradation is in line with observations with BTK inhibitors under similar conditions. BTK degradation was achieved rapidly; in time-course experiments of CLL cells treated with 0.2nM NRX0492 the mean half-live of BTK protein was 2.7 hours (range 2.4h-3h), and at 2nM 99% of BTK was degraded within 4 hours. Next, we tested the rate of recovery of BTK expression after drug washout. After 0.2nm NRX0492 treatment for 4 hours, mean BTK levels were 55% of pre-treatment. After washout and continued culture of cells in complete medium for 96 hours, BTK levels were 41% of pre-treatment. In additional experiments with washout of NRX0492 after 4 hours, we found the lowest levels of BTK 48hours post-treatment, indicating a sustained drug effect. There was no significant difference in the efficacy of BTK degradation between CLL samples subdivided by IGHV mutation status or FISH categories. At 0.2nM NRX0492 for 4 hours, mean remaining BTK was 54% in IGHV mutated and 55% in IGHV unmutated samples (P =0.78), and 60% vs 50% for del(13q) vs del(17p) (P =0.18). Next, we studied samples from two patients progressing on ibrutinib with classic C481S mutations at cancer cell fractions of 50% and 84%, respectively. Both patients remained on ibrutinib at the time of sample collection. After 4 hours of treatment with 0.2nM NRX0492, BTK levels were 50% and 15% of DMSO-treated controls, respectively, consistent with degradation of mutant but not ibrutinib bound BTK. Wild-type BTK bound by ibrutinib is not degraded because ibrutinib prevents NRX0492 binding to BTK. In conclusion, we find NRX0492 is highly effective in degrading BTK in CLL cells. NRX0492 is effective at sub nM concentrations with ED50 ~0.2nM and ED90 ~0.5nM in primary CLL cells. Onset of BTK degradation was rapid and sustained for days after drug washout. NRX0492 was effective across CLL risk groups and equally effective in degrading wild-type BTK and C481S-mutant BTK. Studies testing NRX0492 in vivo in PDX models are ongoing and will inform dosing regimens for clinical studies. Disclosures Kelly: Nurix Therapeutics: Employment. Robbins:Nurix Therapeutics: Employment. Tan:Nurix Therapeutics: Employment. Ingallinera:Nurix Therapeutics: Employment. Sands:Nurix Therapeutics: Employment. Baskar:NIH: Patents & Royalties: ROR1 mAb 2A2. Wiestner:Pharmayclics: Research Funding; Acerta: Research Funding; Merck: Research Funding; Nurix: Research Funding.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
林lin完成签到,获得积分10
1秒前
体贴皮带发布了新的文献求助10
3秒前
MOREMO完成签到,获得积分10
3秒前
CHME完成签到 ,获得积分10
3秒前
酷波er的应助被别梦寒采纳,获得10
3秒前
MYSELF完成签到,获得积分10
6秒前
7秒前
邪恶胡萝卜完成签到,获得积分10
7秒前
幼儿园老大完成签到,获得积分10
9秒前
整齐冬菱发布了新的文献求助10
10秒前
李爱国的应助被察察采纳,获得10
10秒前
xiang完成签到,获得积分10
10秒前
annzhang完成签到,获得积分10
11秒前
MOON完成签到,获得积分10
12秒前
smy发布了新的文献求助10
13秒前
13秒前
tommycat123完成签到 ,获得积分10
14秒前
别梦寒完成签到,获得积分10
14秒前
whb完成签到,获得积分10
15秒前
August完成签到,获得积分10
15秒前
繁花完成签到,获得积分10
15秒前
18秒前
行者发布了新的文献求助20
19秒前
别梦寒发布了新的文献求助10
19秒前
满意夜山完成签到,获得积分10
20秒前
刘刘完成签到,获得积分10
21秒前
自由文博的应助被xiang采纳,获得200
21秒前
hehe发布了新的文献求助10
22秒前
旗亭画壁完成签到 ,获得积分10
22秒前
23秒前
完美世界的应助被非而者厚采纳,获得10
24秒前
CodeCraft的应助被非而者厚采纳,获得10
24秒前
斯文败类的应助被非而者厚采纳,获得10
24秒前
Qw完成签到 ,获得积分10
24秒前
今后的应助被非而者厚采纳,获得10
24秒前
大模型的应助被非而者厚采纳,获得10
24秒前
CodeCraft的应助被非而者厚采纳,获得10
25秒前
25秒前
hvgjgfjhgjh发布了新的文献求助10
25秒前
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191414
求助须知:如何正确求助?哪些是违规求助? 9578277
关于积分的说明 21857909
捐赠科研通 7790787
什么是DOI,文献DOI怎么找? 3436640
关于科研通互助平台的介绍 2560362
邀请新用户注册赠送积分活动 2483366